REGN Quote, Financials, Valuation and Earnings

Bioage Labs has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of --. Regeneron Pharmaceuticals's return on equity of 15.7% beat Bioage Labs's return on equity of --.

Regeneron Pharmaceuticals has a consensus price target of $800.13, signalling upside risk potential of 51.6%. On the other hand Bioage Labs has an analysts' consensus of $6.00 which suggests that it could grow by 48.52%. Given that Regeneron Pharmaceuticals has higher upside potential than Bioage Labs, analysts believe Regeneron Pharmaceuticals is more attractive than Bioage Labs.

Regeneron Pharmaceuticals has a beta of 0.427, which suggesting that the stock is 57.331% less volatile than S&P 500. In comparison Bioage Labs has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.17%. Bioage Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Bioage Labs pays out -- of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are larger than Bioage Labs quarterly revenues of --. Regeneron Pharmaceuticals's net income of $808.7M is higher than Bioage Labs's net income of -$13.6M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.44x while Bioage Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.28x versus -- for Bioage Labs. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of 21.68%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Eli Lilly and's return on equity of 78.25%.

Regeneron Pharmaceuticals has a consensus price target of $800.13, signalling upside risk potential of 51.6%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Regeneron Pharmaceuticals has a beta of 0.427, which suggesting that the stock is 57.331% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.17%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Regeneron Pharmaceuticals's net income of $808.7M is lower than Eli Lilly and's net income of $2.8B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.44x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.28x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of -907.48%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Moderna's return on equity of -29.23%.

Regeneron Pharmaceuticals has a consensus price target of $800.13, signalling upside risk potential of 51.6%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Regeneron Pharmaceuticals, analysts believe Moderna is more attractive than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has a beta of 0.427, which suggesting that the stock is 57.331% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.17%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are larger than Moderna quarterly revenues of $107M. Regeneron Pharmaceuticals's net income of $808.7M is higher than Moderna's net income of -$971M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.44x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.28x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of 21.63%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Pfizer's return on equity of 8.72%.

Regeneron Pharmaceuticals has a consensus price target of $800.13, signalling upside risk potential of 51.6%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 31.27%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Regeneron Pharmaceuticals has a beta of 0.427, which suggesting that the stock is 57.331% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.17%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are smaller than Pfizer quarterly revenues of $13.7B. Regeneron Pharmaceuticals's net income of $808.7M is lower than Pfizer's net income of $3B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.44x while Pfizer's PE ratio is 16.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.28x versus 2.03x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.